Mesenchymal Stem Cell in Pancreatic Islet Transplantation.

Area of Science:

• Immunology
• Regenerative Medicine
• Endocrinology

Background:

• Pancreatic islet transplantation is a key therapy for type 1 diabetes, but graft rejection remains a major challenge.
• Mesenchymal stem cells (MSCs) possess immunomodulatory properties beneficial for transplantation.
• The pancreatic islet graft microenvironment faces stressors like oxidative stress and poor vascularization.

Purpose of the Study:

• To review the role of MSCs in managing the immune response in pancreatic islet transplantation.
• To explore strategies for overcoming challenges such as graft rejection, oxidative stress, and impaired vasculogenesis.
• To highlight novel approaches for enhancing MSC efficacy in islet transplantation.

Main Methods:

• Review of current literature on MSCs in pancreatic islet transplantation.
• Discussion of MSC-mediated immune modulation via cell contact and secretome (exosomes).
• Exploration of preconditioning techniques (hypoxia) and angiogenic stem cells for improving graft survival.

Main Results:

• MSCs act as 'cell managers' controlling immune cells to prevent rejection and promote repair.
• Challenging stressors like oxidative stress and impaired vasculogenesis can negatively impact graft outcomes.
• Novel strategies like hypoxia-preconditioned MSCs and stem cells with angiogenic potential offer solutions.

Conclusions:

• MSCs hold significant potential for improving pancreatic islet transplantation success by modulating the immune system.
• Addressing graft microenvironment stressors through innovative MSC applications is crucial.
• Future research focuses on leveraging MSC stemness and immunomodulatory functions for enhanced therapeutic outcomes in type 1 diabetes.